Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction

Blood

Volumn 89, Issue 1, 1997, Pages 337-344

  Mapara, Markus Y ^a   Körner, Ida J ^b   Hildebrandt, Martin ^b   Bargou, Ralf ^b   Krahl, Dorothea ^b   Reichardt, Peter ^b   Dörken, Bernd ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL SELECTION; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; IMMUNOCYTOCHEMISTRY; LEUKAPHERESIS; LEUKOCYTE COUNT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 1842417177     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.1.337.337_337_344     Document Type: Article

References (35)

1. Shpall EJ, Jones RB. Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SE, Hami L, Taffs S, Heimfeld S, Hallagan J, Berenson RJ: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 12:28, 1994
2. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 85:1647, 1995
3. + progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81:2579, 1993
4. + cells. Blood 84:1408, 1994
5. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, et al: Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 5:891, 1994
6. Karlsson S, Correll PH, Xu L: Gene transfer and bone marrow transplantation with special reference to Gaucher's disease. Bone Marrow Transplant 1:124, 1993
7. Xu L, Stahl SK, Dave HP, Schiffmann R, Correll PH, Kessler S, Karlsson S: Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol. Exp Hematol 22:223, 1994
8. Brugger W, Brass KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636. 1994
9. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994
10. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85, 1993
11. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068, 1994
12. Gribben JG, Arnold MD, Freedman MD, Neuberg D, Roy DC, Blake K, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologie purging of marrow assessed before autologous bone marrow transplantation for B cell lymphoma. N Engl J Med 325:1525, 1991 (abstr)
13. Moss TJ, Ross AA: The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1:225, 1992
14. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, et al: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605, 1993
15. Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S, Koyama H: The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 74:1595, 1994
16. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475, 1994
17. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
18. Bouaboula M, Legoux P, Pessegue B, Delpech B, Dumont X, Piechaczyk M, Casellas P, Shire D: Standardization of mRNA titration using a polymerase chain reaction method involving coamplification with a multispecific internal control. J Biol Chem 267:21830, 1992
19. Hildebrandt M, Mapara M, Körner IJ, Bargou R, Dörken B: Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: A sensitive method for monitoring purging efficiency. Exp Hematol (in press)
20. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219. 1984
21. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Terstappen LWMM, Hardwick A, Moubayed M, Oldham F, Corringham RET, Ho AD: Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 85:275, 1995
22. + selection systems or CAMPATH-1. Exp Hematol 23:147, 1995
23. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B: Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 89:2804, 1992
24. + bone marrow cells. Blood 84:1473, 1994
25. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333:283, 1995
26. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 84:1421, 1994
27. Kiesel S, Haas R, Moldenhauer G, Kvalheim G, Pezzutto A, Dörken B: Removal of cells from a malignant B cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis. Leuk Res 11:1119, 1987
28. Kvalheim G, Fodstad O, Pihl A, Nustad K, Pharo A, Ugelstad J, Funderud S: Elimination of B-lymphoma cells from human bone marrow: Model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies. Cancer Res 47:846, 1987
29. Santos GW, Colvin M: Pharmacological purging of bone marrow with reference to autografting. Clin Haematol 15:67, 1986
30. Muirhead M, Martin PJ, Torok-Storb B, Uhr J, Vitetta ES: Use of antibody-ricin A chain conjugate to delete neoplastic B cells from human bone marrow. Blood 62:327, 1983
31. Myklebust AT, Godal A, Juell S, Pharo A, Fodstad Ø: Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 54:209, 1994
32. Nollau P, Jung R, Neumaier M, Wagener C: Tumour diagnosis by PCR-based detection of tumour cells. Scand J Clin Lab Invest Suppl 221:116. 1995
33. Neumaier M, Gerhard M, Wagener C: Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 159:43, 1995
34. Gullick WJ: The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer 5:55. 1990 (suppl)
35. Schulze R, Schulze M, Wischnik A, Ehnle S, Doukas K, Behr R, Schlimok G: Tumor cell contamination of peripheral blood stem cell transplants (PBSCT) and/or bone marrow (BM) in high risk breast cancer patients (N >10). Blood 86:234a, 1995 (abstr, suppl 1)